Patients who meet certain criteria volunteer to participate in carefully conducted investigations that discover better ways to treat, prevent, diagnose, and understand human disease – including Chronic Kidney Disease. Here at Frenova Baton Rouge, we specialize in Renal research.
Our team is focused on supporting our research patients while advancing renal care. All research studies are approved by the FDA and are continuously monitored by the IRB - a group unconnected to the research team that reviews each study to ensure patient rights, safety standards and protocol. Not only do participants help us improve and advance kidney treatment, they often become more knowledgeable and engaged in their own kidney care.
Frenova, part of Fresenius Medical Care North America (FMCNA), is a team of renal research experts that operate at the convergence of clinical research and renal patient care. No other clinical development services provider works with a more intimate understanding of patients affected by kidney disease and its comorbid conditions than we do. Frenova provides access to the largest renal research site network in the world.
Our Baton Rouge site is led by Principal Investigator Dr. Michael Roppolo, who explains that “By allowing Frenova to direct the clinical research staff and trial operations, we can enroll more patients into studies and ultimately help patients by introducing new advances and treatments to the market.”
Frenova Baton Rouge is a member of the Frenova F1RST Up alliance, a highly select group of sites chosen for their expertise in renal research and track record of rapid patient recruitment and retention.
Since Frenova has partnered with Renal Associates, we have tripled in size, in staff and research studies that are offered. We look forward to benefitting our patients in the years to come!
Humacyte V007 – Vascular Access NCT03183245
A phase 3 study to compare the efficacy and safety of Humacyte’s Human Acellular Vessel with that of an autologous arteriovenous fistula in subjects with end-stage renal disease receiving dialysis via dialysis catheter.
Sanifit 06 – Calciphylaxis: NCT04195906
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis in dialysis patients.
Bayer 20115 – Anti-coagulation: NCT04523220
A study to assess the safety and tolerability of Osocimab to ESRD Patients on Regular Hemodialysis. Osocimab is a human monoclonal antibody under development for the prevention of heart attack, stroke and death caused by blood clots.
Vertex VX19-147-101 – FSGS: NCT04340362
Phase 2, open-label, single-arm study to evaluate the ability of oral VX-147 to reduce proteinuria via modulation of the APOL1 pathway in patients with APOL1 mediated FSGS. Genotyping provided by sponsor.
Vertex VX19-NEN-801 – APOL1 Genetic Test - Proteinuric Kidney Disease
Genetic study of the prevalence of APOL1 alleles who are of recent African ancestry or geographic origin. No study drug will be administered. A blood sample will be collected.
Reata 402-C-1808 – Bardoxolone methyl – ADPKD: NTC03918447
A Phase 3 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients with ADPKD who are not on Tolvaptan.
Visterra VIS649-201 – Immunoglobulin A Nephropathy: NCT04287985
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy (IgAN).
Novartis CLNP023A2301 - Immunoglobulin A Nephropathy: NCT04578834
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients.
Boehringer Ingelheim 1366-0022 – Non-diabetic Chronic Kidney Disease: NCT04736628
A study to test the effect of different doses of BI 685509 on kidney function in people with chronic kidney disease who do not have diabetes.